SNSE
Sensei Biotherapeutics, Inc.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.26
P/S
-8.68
EV/EBITDA
-1.67
DCF Value
$5.68
FCF Yield
-48.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
459.5%
Net Margin
434.7%
ROE
-83.6%
ROA
-92.1%
ROIC
-110.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-4.7M | $-8.92 |
| FY 2025 | $0.00 | $-21.1M | $-16.72 |
| Q3 2025 | $-4.9M | $-4.6M | $-3.62 |
| Q2 2025 | $0.00 | $-4.9M | $-3.91 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$5.50
Target (Median)
$5.50
Target Range
$5.00 - $6.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.10
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.